Versant Venture Capital V L.P. 13D and 13G filings for Crinetics Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
2022-02-10 8:21 pm Sale | 2021-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX | Versant Venture Capital V L.P. | 382,961 0.800% | -1,512,041![]() (-79.79%) | Filing |
2021-02-12 8:27 pm Sale | 2020-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX | Versant Venture Capital V L.P. | 1,895,002 5.800% | -789,560![]() (-29.41%) | Filing |